

Gates Institute Cell and Gene Therapy

Product Pipeline



Current Products

- CD19 CAR T: blood cancers
 - Adult relapsed/refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
 - Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
 - Pediatric relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
 - Pediatric relapsed/refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
- CD19x22 CAR T: blood cancers
 - Adult relapsed/refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
 - Pediatric relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- CD19 CAR T: autoimmune disease
 - Adolescent Refractory Lupus Nephritis (LN)
 - Adolescent Polyarticular Juvenile Idiopathic Arthritis (pJIA) with severe refractory disease course

Pipeline Immune Effector Cell (IEC) Products

- CAR T: Acute Myeloid Leukemia (AML)
- CAR T: solid tumors
- CAR T: brain tumors
- Engineered Tumor-Infiltrating Lymphocytes (TILs): solid tumors

Pipeline iPSC Products

- iPSC: Age-Related Macular Degeneration (AMD)
- iPSC: Epidermolysis Bullosa (EB)

CAR = chimeric antigen receptor; iPSC = induced pluripotent stem cell; IND = investigational new drug